Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Study Underscores Importance of Personalized Medicine in Kidney Cancer


 

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.

The study published Thursday, Nov. 5, in Cancer Cell is a comprehensive molecular analysis of 823 tumors donated by patients with advanced renal cell carcinoma (RCC) who were either treated with the immunotherapies atezolizumab and bevacizumab in combination or the targeted therapy sunitinib.

Researchers validated for the first time the prognostic and predictive capability of transcriptional signatures and described the distinct molecular subtypes that associate with different outcomes to these cancer treatments. They also identified additional molecular targets for future drug development

"These data were a massive undertaking and are the most comprehensive analysis of RCC tumors from a phase 3 trial to date. They further refine the known angiogenic and inflammatory biology of RCC, but also shed light on proliferative and metabolic pathways that are relevant." said Brian Rini, MD, Ingram Professor of Cancer Research and chief of Clinical Trials at Vanderbilt-Ingram Cancer Center (VICC), the study's senior author

Approximately 25% of renal cell carcinoma patients have metastatic cancer at the time of diagnosis, and studies of tumors taken from those patients indicate that 20% of those specimens include a sarcomatoid component. Patients with metastasized cancer whose tumors that include a sarcomatoid component have poor clinical prognosis. Of the 823 tumors studied, 134 had sarcomatoid features.

The researchers identified seven tumor subsets for renal cell carcinoma, including those with sarcomatoid features. The seven molecular subsets are identified in an illustration on the first page of the study along with which treatment had better efficacy. The seven subtypes are Angiogenic/Stromal, Angiogenic, Complement/W-oxidation, T-effector/Proliferative, Stromal/Proliferative and snoRNA.

These data can be used to tailor a biomarker-based approach to select specific therapies for specific patients. This will require further validation of these clusters in prospective trials.

The study highlights the importance of personalized medicine and molecular tumor boards in guiding treatment decisions. Molecular tumor boards are composed of highly specialized cancer experts, including genomics specialists. VICC has a molecular tumor board composed of medical oncologists, molecular pathologists, lab scientists, genetics counselors and bioinformatics experts.

 
Share:

Related Articles:


Recent Articles

New Study Identifies Gaps in Treatment for Opioid Use Disorder as Overdose Emergencies Soar

Opioid overdose deaths have reached record highs and emergency physicians have a vital role in potentially saving these patients by prescribing Medication Assisted Treatment (MAT) such as buprenorphine, and by prescribing naloxone, a rapid-acting medicine to reverse an overdose.

Read More

HealthStream Acquires Rievent Technologies

Leveraging its hStream open architecture, HealthStream expands its ecosystem with a powerful continuing education management and delivery application

Read More

INTERNATIONAL VOLUNTEER DAY: LOCAL PEDIATRICIAN TERRI WHITE DEDICATES TIME TO HELP CHILDREN WORLDWIDE

International Volunteer Day is a global celebration of volunteers. It takes place every year on December 5 to shine a light on the impact of volunteer efforts everywhere.

Read More

Tivity Health Takes Meaningful Steps to Keep Seniors Engaged, Connected

At first glance, SilverSneakers might appear to be 'just' a fitness class ... but dig a bit deeper, and it's clear this class is actually a community keeping participants active and engaged.

Read More

AMA Adopts Policy to Combat Public Health Disinformation by Health Care Professionals

New policy aims to address spread of rampant disinformation amid COVID-19 pandemic

Read More

AMA Adopts Policy Aimed at Strengthening U.S. Public Health Infrastructure, Opposing Limits Placed on Public Health Officials

New policy calls for consistent, sustainable funding, a robust public health workforce, and data modernization

Read More

Managing Risk of Cyber Incidents

Cyber threats are here to stay -- and they continue to be one of the topics keeping senior management up at night. With breaches and ransomware attacks still occurring at high rates, the healthcare industry continues to be significantly impacted.

Read More

American Cancer Society, Meharry Team Up to Change the Narrative

Meharry Medical College is one of four HBCUs partnering with the American Cancer Society.

Read More

Navigating Cancer Care

Nashville startup Thyme Care is proving to be an innovator in the cancer navigation space.

Read More

ONcology Rounds

New treatments, research and leadership - Middle Tennessee has a lot going on in oncology care.

Read More

Email Print
 
 

 

 


Tags:
oncology
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: